Kiora Pharmaceuticals INC 8-K filings

Kiora Pharmaceuticals announced its second quarter 2026 financial results, highlighting progress in its Phase 2 trials for KIO-301 and KIO-104, and an extended operational runway into late 2028.

Kiora Pharmaceuticals announced preclinical data demonstrating that its ion channel modulator, KIO-300, significantly suppressed seizure-associated electrophysiological activity in an ex vivo temporal lobe epilepsy model.

Kiora Pharmaceuticals announced first quarter 2026 financial results and provided updates on its clinical pipeline, highlighting active enrollment in Phase 2 studies and a strengthened balance sheet.

Kiora Pharmaceuticals has closed a private placement financing for $5 million in upfront gross proceeds with up to $19 million in potential future warrant exercises.

Kiora Pharmaceuticals announced the departure of its Chief Development Officer, Eric J. Daniels, M.D., MBA, effective April 17, 2026, to pursue other opportunities.

Kiora Pharmaceuticals announced full-year 2025 financial results and significant progress in its Phase 2 clinical trials for retinal diseases, extending its cash runway into late 2027.

Kiora Pharmaceuticals announced third quarter 2025 financial results, reporting net income of $27 thousand, and provided updates on its two actively enrolling Phase 2 clinical trials for retinal diseases.

Kiora Pharmaceuticals highlights positive clinical data for KIO-301 and KIO-104, targeting significant unmet needs in retinal diseases.

Kiora Pharmaceuticals reported Q2 2025 financial results and significant progress in its Phase 2 clinical trials for retinal diseases, extending its cash runway into late 2027.

Kiora Pharmaceuticals, Inc. announced that its stockholders approved all proposals at the Annual Meeting held on June 4, 2025, including the re-election of two Class I Directors and the ratification of its independent accounting firm.

Kiora Pharmaceuticals has entered into an exclusive option agreement with Senju Pharmaceutical for KIO-301 in key Asian markets, potentially bringing in $110 million plus royalties and extending Kiora's cash runway into late 2027.

Kiora Pharmaceuticals reported its first quarter 2025 financial results, highlighting progress in its retinal disease therapeutic pipeline and an extended cash runway into late 2027.

Kiora Pharmaceuticals reports 2024 financial results, highlights progress in retinal disease drug development, and anticipates cash runway into 2027.

Kiora Pharmaceuticals has formalized employment agreements with its Chief Development Officer, Eric Daniels, and Chief Financial Officer, Melissa Tosca, outlining compensation, benefits, and termination terms.

Kiora Pharmaceuticals reports positive progress in its retinal disease pipeline, including the advancement of two Phase 2 clinical trials and a solid cash position, as of the third quarter of 2024.

Kiora Pharmaceuticals has received regulatory approval to begin a Phase 2 clinical trial for KIO-301, a potential treatment for retinitis pigmentosa.

Kiora Pharmaceuticals reports second quarter 2024 results, highlighting progress in its retinal disease drug development pipeline, including two Phase 2 studies.

Kiora Pharmaceuticals has been granted Orphan Medicinal Product Designation in Europe for KIO-301, a treatment for inherited retinal dystrophies, providing market exclusivity and other benefits.

Kiora Pharmaceuticals has appointed Lisa Walters-Hoffert to its Board of Directors, named Melissa Tosca as Chief Financial Officer, and adjusted executive compensation, while also regaining compliance with Nasdaq's minimum bid price requirement.

Kiora Pharmaceuticals has enacted a 1-for-9 reverse stock split to comply with Nasdaq's minimum bid price requirement, effective June 11, 2024.

Kiora Pharmaceuticals announced positive first quarter 2024 financial results, highlighted by a $16 million upfront payment from a strategic partnership and progress in clinical development of their retinal disease treatments.

Kiora Pharmaceuticals' stockholders approved an increase in authorized shares and a reverse stock split, among other proposals, at their 2024 Annual Meeting.

Kiora Pharmaceuticals announces 2023 financial results, a strategic partnership with TOI, and a private placement, securing funding through 2026 and advancing its pipeline for rare retinal diseases.

Kiora Pharmaceuticals is advancing its retinal therapeutics pipeline, including KIO-301 for inherited retinal diseases and KIO-104 for non-infectious uveitis, with key clinical milestones expected in the coming quarters.

Kiora Pharmaceuticals has announced a private placement to raise up to approximately $45 million, including $15 million upfront and up to $30 million from potential warrant exercises.

Kiora Pharmaceuticals has entered into a strategic agreement with Tha Open Innovation for the development and commercialization of KIO-301, a treatment for inherited retinal diseases, potentially worth up to $301 million.

Kiora Pharmaceuticals has been granted a second 180-day extension by Nasdaq to regain compliance with the minimum bid price requirement.